279 filings
DEFA14A
RLMD
Relmada Therapeutics Inc
9 Apr 24
Additional proxy soliciting materials
4:15pm
DEF 14A
RLMD
Relmada Therapeutics Inc
Definitive proxy
9 Apr 24
4:10pm
8-K
RLMD
Relmada Therapeutics Inc
19 Mar 24
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
4:10pm
10-K
2023 FY
RLMD
Relmada Therapeutics Inc
Annual report
19 Mar 24
4:05pm
8-K
RLMD
Relmada Therapeutics Inc
11 Jan 24
Departure of Directors or Certain Officers
4:30pm
8-K
4bqm 1a3ksh
4 Jan 24
Relmada Therapeutics Provides Corporate Update
8:11am
8-K
x1v6g tlrgc7c
3 Jan 24
Departure of Directors or Certain Officers
5:00pm
8-K
zl3lvyj
8 Nov 23
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:01pm
8-K
vz6 wgpzygi
11 Oct 23
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver MeetingĀ® 2023
9:00am
8-K
9z5hzqj6 blteq
10 Oct 23
Targeting Major Advances in the Treatment of CNS Disorders October 10 th , 2023
5:18pm
8-K
osdrmsa iizo66
4 Oct 23
Targeting Major Advances in the Treatment of CNS Disorders October 4 th , 2023
8:53am
8-K
vmgwrnf h1kct2
20 Sep 23
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
4:47pm
8-K
ws2q7
6 Sep 23
Departure of Directors or Certain Officers
9:23am
8-K
vylsd15lyq1mi
10 Aug 23
Targeting Major Advances in the Treatment of CNS Disorders August 10 th , 2023
4:54pm
8-K
0xc87x7o zftufahyp
8 Aug 23
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:29pm
S-8
9fiwotlqyg1
21 Jun 23
Registration of securities for employees
5:00pm
8-K
eou6p3ua
25 May 23
Departure of Directors or Certain Officers
4:28pm
8-K
ugwovtuk0hj
15 May 23
Targeting Major Advances in the Treatment of CNS Disorders May 15 th , 2023
5:29pm